Catalase-Functionalized Iron Oxide Nanoparticles Reverse Hypoxia-Induced Chemotherapeutic Resistance.
Animals
Basic Helix-Loop-Helix Transcription Factors
/ metabolism
Breast Neoplasms
/ therapy
Catalase
/ chemistry
Cell Line, Tumor
Cell Survival
Drug Resistance, Multiple
/ drug effects
Drug Resistance, Neoplasm
/ drug effects
Female
Ferric Compounds
/ chemistry
Humans
Hypoxia
Hypoxia-Inducible Factor 1, alpha Subunit
/ metabolism
Metal Nanoparticles
/ chemistry
Mice
Oxidative Stress
Paclitaxel
/ pharmacology
Spectroscopy, Fourier Transform Infrared
Treatment Outcome
breast cancer
catalase
drug delivery
hypoxia-inducible factors
iron oxide nanoparticles
Journal
Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
26
06
2019
revised:
15
08
2019
pubmed:
27
9
2019
medline:
23
9
2020
entrez:
27
9
2019
Statut:
ppublish
Résumé
Intratumoral hypoxia is a major contributor to multiple drug resistance (MDR) in cancer, and can lead to poor prognosis of patients receiving chemotherapy. Development of an MDR-inhibitor that mitigates the hypoxic environment is crucial for cancer management and treatment. Reported is a biocompatible and biodegradable catalase-conjugated iron oxide nanoparticle (Cat-IONP) capable of converting reactive oxygen species to molecular oxygen to supply an oxygen source for the hypoxic tumor microenvironment. Cat-IONP demonstrates initial enzymatic activity comparable to free catalase while providing a nearly threefold increase in long-term enzymatic activity. It is demonstrated that Cat-IONP significantly reduces the in vitro expression of hypoxia-inducible factors at the transcription level in a breast cancer cell line. Co-treatment of Cat-IONP and paclitaxel (PTX) significantly increases the drug sensitivity of hypoxic-cultured cells, demonstrating greater than twofold and fivefold reduction in cell viability in comparison to cells treated only with 80 and 120 × 10
Identifiants
pubmed: 31557421
doi: 10.1002/adhm.201900826
pmc: PMC6919328
mid: NIHMS1053018
doi:
Substances chimiques
Basic Helix-Loop-Helix Transcription Factors
0
Ferric Compounds
0
HIF1A protein, human
0
Hypoxia-Inducible Factor 1, alpha Subunit
0
endothelial PAS domain-containing protein 1
1B37H0967P
ferric oxide
1K09F3G675
Catalase
EC 1.11.1.6
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1900826Subventions
Organisme : NIBIB NIH HHS
ID : R01 EB026890
Pays : United States
Organisme : Kyocera Professor Endowment
Pays : International
Organisme : NSF
ID : NNCI-1542101
Pays : International
Informations de copyright
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Références
Curr Drug Targets. 2014;15(13):1177-99
pubmed: 25341421
Drug Deliv Transl Res. 2011 Dec 1;1(6):409-19
pubmed: 22201014
Nat Rev Drug Discov. 2006 Mar;5(3):219-34
pubmed: 16518375
Cancer Metastasis Rev. 2007 Jun;26(2):281-90
pubmed: 17603752
Proc Natl Acad Sci U S A. 2011 Sep 27;108(39):16369-74
pubmed: 21911388
Nano Life. 2013 Dec 27;3(4):
pubmed: 25414730
Biochim Biophys Acta. 2016 Mar;1863(3):382-391
pubmed: 26079100
Biochim Biophys Acta. 2007 Sep;1767(9):1073-101
pubmed: 17692815
N Engl J Med. 2011 Aug 11;365(6):537-47
pubmed: 21830968
Small. 2009 Jul;5(14):1637-41
pubmed: 19334014
Drug Resist Updat. 2017 Mar;31:15-30
pubmed: 28867241
Cancer Metastasis Rev. 2007 Jun;26(2):241-8
pubmed: 17440683
Biochim Biophys Acta. 1964 Jul 8;89:47-65
pubmed: 14213012
Cell Stem Cell. 2011 Apr 8;8(4):399-411
pubmed: 21474104
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Trends Pharmacol Sci. 2012 Apr;33(4):207-14
pubmed: 22398146
Drug Resist Updat. 2011 Jun;14(3):191-201
pubmed: 21466972
Oncogenesis. 2016 Jan 25;5:e190
pubmed: 26807645
Oxid Med Cell Longev. 2018 Sep 30;2018:8238459
pubmed: 30363917
Methods Enzymol. 1995;246:501-26
pubmed: 7752935
ACS Nano. 2013 Aug 27;7(8):6667-6673
pubmed: 23815280
J Biol Chem. 1995 Jun 23;270(25):15434-42
pubmed: 7797532
Cancer Cell. 2009 Jun 2;15(6):501-13
pubmed: 19477429
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17910-5
pubmed: 19805192
J Biol Chem. 2007 Jan 12;282(2):1183-92
pubmed: 17105724
J Physiol. 2013 Apr 15;591(8):2027-42
pubmed: 23401619
Enzyme Microb Technol. 2001 Jun 7;28(9-10):815-819
pubmed: 11397463
Nat Rev Cancer. 2014 Nov;14(11):709-21
pubmed: 25342630
J Immunol Methods. 1997 Mar 28;202(2):133-41
pubmed: 9107302
Nat Nanotechnol. 2010 Jun;5(6):465-72
pubmed: 20383126
Oncogene. 2015 Aug 20;34(34):4482-90
pubmed: 25417700
Nanomedicine (Lond). 2008 Oct;3(5):703-17
pubmed: 18817471
Cancer Cell. 2007 May;11(5):407-20
pubmed: 17482131